Phyllis McKiernan on Patient Age and Transplant Performance

Video

Phyllis McKiernan discusses appropriate age and other factors for transplants.

Phyllis McKiernan, APN, John Theurer Cancer Center, discusses new findings about patient age and transplant possibilities.

While patients older than 65 previously weren't considered for transplant, new data suggest that transplant can be appropriate even for patients older than 75. Rather than looking at age, McKiernan suggests considering a patient's performance status. This allows the risk to be mitigated so that all patients have the best possible outcome and disease control.

Related Videos
Testi
Patrick Buxton, RN, BSN
Cheryl VerStrate on the Pitfalls of Direct-to-Consumer Genetic Tests
Elizabeth Aronson
MPN-Associated Anemia: What Nurses Should Look Out For
Cancer-Related Cognitive Impairment
Charina Toste
Lindsey Lyle
Related Content
blood cancer

Opinion: CAR T-Cell Therapy Remains a Promising Therapeutic Option Despite FDA Inquiry into Secondary Malignancies

December 5th 2023
Article

Oncology nurses should be ready to offer informative guidance to patients and their families concerning the ongoing FDA inquiry and its potential impact.

Laura Zitella Discusses the Growing Arsenal of Bispecific Antibodies in DLBCL

Laura Zitella Discusses the Growing Arsenal of Bispecific Antibodies in DLBCL

December 1st 2023
Podcast

Laura Zitella, MS, RN, ACNP-BC, AOCN, discusses how newly approved bispecific antibodies are expanding third-line treatment options for patients with diffuse large B-cell lymphoma.

FDA

FDA Is Investigating Potential Secondary Cancer Risks Associated CAR T-Cell Therapy

November 30th 2023
Article

There have been reports of T-cell malignancies among patients who have undergone CD19- or BCMA-directed autologous CAR T-cell immunotherapies.

Beth Faiman Discusses Recent Changes in Multiple Myeloma Treatment Landscape

Beth Faiman Discusses Recent Changes in Multiple Myeloma Treatment Landscape

April 13th 2023
Podcast

Beth Faiman, PhD, CNP, discusses reclassifying patients with multiple myeloma, the accelerated approval of teclistamab, and the removal of belantamab mafodotin from the US market.

blood cells

Copanlisib Will No Longer Be Available in the US for Relapsed Follicular Lymphoma

November 24th 2023
Article

Manufacturers have announced that they will be withdrawing the new drug application for copanlisib in adult patients with relapsed follicular lymphoma.

FDA

FDA Launches Priority Review of Liso-Cel in Pretreated CLL/SLL

November 10th 2023
Article

Lisocabtagene maraleucel is under consideration as a potential treatment option for patients with chronic lymphocytic leukemia or small lymphocytic lymphoma.

© 2023 MJH Life Sciences

All rights reserved.